CLINICAL TRIALS PROFILE FOR VARESPLADIB METHYL
✉ Email this page to a colleague
Clinical Trials for Varespladib methyl
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00743925 ↗ | FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes | Completed | Anthera Pharmaceuticals | Phase 2 | The objective of this study is to evaluate the safety and efficacy of A 002 when added to high dose atorvastatin in subjects with an acute coronary syndrome (ACS) |
NCT01130246 ↗ | VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome | Terminated | Anthera Pharmaceuticals | Phase 3 | The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS). |
NCT01359579 ↗ | A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function | Terminated | Anthera Pharmaceuticals | Phase 1 | The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of varespladib methyl in mild or moderate renal impairment patients and healthy volunteers. |
NCT01359605 ↗ | Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects | Completed | Anthera Pharmaceuticals | Phase 1 | The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of [14C]varespladib methyl. |
NCT04996264 ↗ | Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite | Recruiting | Premier Research International LLC | Phase 2 | This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of varespladib-methyl, concurrently with standard of care (SOC), in subjects bitten by venomous snakes. |
NCT04996264 ↗ | Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite | Recruiting | Ophirex, Inc. | Phase 2 | This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of varespladib-methyl, concurrently with standard of care (SOC), in subjects bitten by venomous snakes. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Varespladib methyl
Condition Name
Clinical Trial Locations for Varespladib methyl
Trials by Country
Clinical Trial Progress for Varespladib methyl
Clinical Trial Phase
Clinical Trial Sponsors for Varespladib methyl
Sponsor Name